Long-term follow-up of posterior capsule opacification after AquaLase and NeoSoniX phacoemulsification

Alexandr Stepanov, Jana Nekolova, Nada Jiraskova, Pavel Rozsival

Aim. To compare the degree of posterior capsule opacification (PCO) after AquaLase and NeoSoniX phacoemulsification methods during an 8-year follow-up period using two types of software.

Design. Prospective, randomized clinical trial.

Methods. AquaLase was used in the right eye and NeoSoniX in the left eye of each patient with bilateral cataract.

Results. Fifty patients were analyzed 1 year, 46 patients 3 years, and 37 patients 8 years after cataract surgery. Mean EPCO 2000 values were for the AquaLase group 0.324 ± 0.305 and for the NeoSoniX group 0.298 ± 0.341 (P = 0.53) 1 year after surgery, for the AquaLase group 0.582 ± 0.506 and for the NeoSoniX group 0.594 ± 0.515 (P = 0.87) 3 years after surgery, and for the AquaLase group 0.648 ± 0.567 and for the NeoSoniX group 0.673 ± 0.542 (P = 0.30) 8 years after surgery. The OSCA results were for the AquaLase group 0.7097 ± 0.3778 and for the NeoSoniX group 0.8584 ± 0.4323 (P = 0.046) 1 year after surgery, for the AquaLase group 0.9667 ± 0.736 and for the NeoSoniX group 0.9540 ± 0.5250 (P = 0.91) 3 years after surgery, and for the AquaLase group 1.035 ± 0.952 and for the NeoSoniX group 1.103 ± 0.741 (P = 0.44) 8 years after surgery.

Conclusion. There was minimal PCO difference between these 2 approaches, AquaLase and NeoSoniX. Neither AquaLase nor NeoSoniX technique was able to prevent a natural progression of PCO.

Key words: posterior capsule opacification, AquaLase, NeoSoniX

INTRODUCTION

Posterior capsule opacification (PCO) is one of the most common complications of cataract extraction with intraocular lens (IOL) implantation, occurring in 36% to 97% of cases in the first 2-4 years after extracapsular cataract surgery. Since the PCO usually develops over years and leads to a slow decrease in visual acuity (VA), progression over time is the important factor in PCO evaluation. Advances in surgical technique and IOL design may decrease the amount of PCO after cataract extraction. In recent years, perioperative pharmacological modifications and changes in IOL design have been made to reduce the incidence of PCO (ref.8,9). However, the most critical factors to reduce PCO involve removal of as many residual epithelial cells as possible, proper placement of the IOL inside the capsular bag, a capsulorrhexis size that is smaller than the IOL optics, and use of an IOL with sharp-edged optics10,11.

The goal of this study was to examine the progression of PCO through 8 years in eyes after 2 different irrigation/aspiration techniques (AquaLase and NeoSoniX) of cataract surgery in which AcrySof SA60AT (Alcon Laboratories, Fort Worth, Texas, USA) sharp-edged silicone intraocular lenses. We used the Evaluation of Posterior Capsule Opacification (EPCO) 2000 software (Berlin, Germany) for morphologic scoring of PCO and the Open-Access Systematic Capsule Assessment (OSCA) system (Edinburgh, United Kingdom) for PCO analysis.

The previous results of this study after 1, 2 and 3-year follow-up have been published12. In order to investigate whether the difference in PCO rates after AquaLase and NeoSoniX phacoemulsification was consistent over longer period of time, an 8-year follow-up was performed.

METHODS

Study design, image acquisition, and computer analysis of PCO, as well as the statistical methods and sample size calculation used, were exactly the same as in our previous publication12. Thirty-seven patients of the original 62 were included in the study. The inclusion criteria were bilateral nonbrunescent cataract (according to the Buratto classification, a cataract grade of less than 5) (ref.13) and no other severe ocular pathologic features potentially affecting VA (patients with mild age-related macular degeneration were not excluded). Both eyes of each patient involved in the study had cataract with similar density grade. All surgeries were performed in the years 2004 and 2005 at the Department of Ophthalmology, University Hospital in Hradec Kralove. The AquaLase was used in the right eye and NeoSoniX was used in the left eye of
Sixty-two patients eligible for the study were originally included. Fifty patients completed 1-year follow-up examination, 46 of them attended 1-year and 3-year follow-up examinations, and 37 participants completed all 8-year follow-up examinations. Nd:YAG laser capsulotomy rate for AquasLase vs NeoSoniX was 0:1 eyes 1 year postoperatively, 1:4 eyes 3 years after surgery and 2:6 eyes after 8 years. Thus, the PCO of 49 patients were computer analyzed 1 year after surgery, 42 patients were included in the computer PCO analysis 3 years postoperatively, and PCO of 37 patients were computer analyzed after 8-year follow-up.

The mean OSCA scores, the mean total EPCO 2000 indexes, and P values of paired t test analysis, each for the right eye operated on by using AquasLase phacoemulsification and for the left eye after NeoSoniX cataract removal method, are shown in Table 1. There are 1-year, 3-year, and 8-year results.

The summary graph illustrating development of PCO after the AquasLase and the NeoSoniX method for each measurement type, EPCO 2000 and OSCA, within the 8-year follow-up period is shown in Fig. 1. The comparison of PCO after AquasLase and NeoSoniX phacoemulsification is shown in Fig. 2. There are mean total EPCO 2000 indexes and OSCA scores, with error bars.

An increase in EPCO 2000 indexes was found during the 8-year period, after both AquasLase and NeoSoniX cataract removal method (P < 0.05). A significant increase was proved in the EPCO 2000 outcomes between the first and third postoperative years. The difference in the EPCO 2000 scores between the third and eight postoperative years was not significant.

The difference in the OSCA indexes between the first and third and between the third and eight postoperative years was significant; the scores was nonsignificantly higher in the AquasLase group, 8 years after surgery (P = 0.41), whereas in the NeoSoniX group it was significantly higher in the eight year (P = 0.68). A significant increase was proved in the OSCA outcomes between the first and the third postoperative year, after both AquasLase and NeoSoniX phacoemulsification method (P < 0.05).

The comparison of PCO after the AquasLase and the NeoSoniX technique was done. The EPCO 2000 results were as follows: after 1 year, there was no proven significant difference between the AquasLase and the NeoSoniX group; the mean total EPCO index was slightly better for
Table 1. Mean Values With Standard Deviation of Total Evaluation of Posterior Capsule Opacification 2000 Indexes and Open-Access Systematic Capsule Assessment Scores for the AquaLase and the NeoSoniX Group, 1, 3 and 8 Years After Cataract Surgery.

<table>
<thead>
<tr>
<th></th>
<th>1 Year Postoper.</th>
<th>3 Years Postoper.</th>
<th>8 Years Postoper.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AqL</td>
<td>NSX</td>
<td>P value</td>
</tr>
<tr>
<td>EPCO mean value</td>
<td>0.324</td>
<td>0.298</td>
<td>0.53</td>
</tr>
<tr>
<td>EPCO SD</td>
<td>0.305</td>
<td>0.341</td>
<td></td>
</tr>
<tr>
<td>OSCA mean value</td>
<td>0.709</td>
<td>0.858</td>
<td>0.046*</td>
</tr>
<tr>
<td>OSCA SD</td>
<td>0.378</td>
<td>0.432</td>
<td></td>
</tr>
</tbody>
</table>

n = 49
n = 42
n = 34

AqL = AquaLase; EPCO = Evaluation of posterior capsule opacification; NSX = NeoSoniX; OSCA = Open-Access Systematic Capsule Assessment; SD = standard deviation.

Comparison of posterior capsule opacification after AquaLase and NeoSoniX; P values of paired t test.

*P < 0.05 (confidence interval alpha) showed a significant difference.

Fig. 1. Summary graph illustrating the development of posterior capsule opacification (PCO) after the AquaLase (AqL) and the NeoSoniX (NSX) method for each measurement. Evaluation of Posterior Capsule Opacification (EPCO) 2000 and Open-Access Systematic Capsule Assessment (OSCA). Mean values with error bars. One-year (1Y), 2-year (2Y), and 5-year (5Y) results. Considerable increase in the mean total EPCO indexes was found during the 3Y period, after both AquaLase and NeoSoniX cataract removal method. The OSCA score was higher in the AquaLase group 3 years after surgery, whereas in the NeoSoniX group it was only nonsignificantly higher in the third year. A nonsignificant increase was proved in the EPCO outcomes between the third and the eight postoperative year and in the OSCA outcomes after AquaLase method. The OSCA score was significantly higher in the NeoSoniX group 8 years after surgery. White bars = AquaLase group; gray bars = NeoSoniX group.

Fig. 2. Comparison of mean total EPCO 2000 indexes and OSCA scores after AqL and NSX phacoemulsification 1, 3, and 8 years after cataract surgery, with error bars. The difference in EPCO 2000 outcomes was not significant. There was a significant difference in OSCA scores 1 year and 8 years postoperatively and nonsignificant difference 3 years postoperatively. White bars = AquaLase group; gray bars = NeoSoniX group.
The NeoSoniX group, Whereas in 3-year and 8-year results the AquaLase showed better outcomes, the difference was not significant. The mean EPCO 2000 indexes with standard deviation of all EPCO grades and of total EPCO index for the AquaLase and the NeoSoniX group, 1, 3, and 8 years after cataract surgery are shown in Table 2. There was an increase in PCO density within the whole follow-up period; there were more PCO assessed with higher EPCO grades. The PCO scores obtained with the OSCA system were worse for the NeoSoniX group 1 and 8 years after cataract surgery, unlike the 3-year results, when the mean OSCA score was nonsignificantly better for the NeoSoniX group. There was low correlation between the EPCO and OSCA results, 1, 3, and 8 years postoperatively. There was no significant difference in the BCVA between the AquaLase and the NeoSoniX group. One year after surgery, the BCVA was 0.837 ± 0.262 for the right eyes (AquaLase group) and 0.849 ± 0.224 for the left eyes (NeoSoniX group). The mean BCVA was 0.886 ± 0.197 for the AquaLase group and 0.842 ± 0.211 for the NeoSoniX group 3 years after cataract surgery and 0.834 ± 0.07 for the right eyes and 0.825 ± 0.08 for the left eyes 8 years postoperatively. Most eyes (85% on average) achieved BCVA 0.8 and better (0.8 to 1.2).

There was no significant increase in BCVA between the first and the third postoperative year in the AquaLase group, \( P = 0.006 \); and nonsignificant decrease in the NeoSoniX group, \( P = 0.11 \). And between the third and eight year, the BCVA nonsignificant decreased.

**DISCUSSION**

Posterior capsular opacification is the most frequent complication of cataract surgery. Advances in surgical techniques, intraocular lens materials, and designs have reduced the PCO rate, but it is still a significant problem.\(^{17-19}\) Patients with mild age-related macular degeneration were not excluded from this study; this disease might also have an impact on the postoperative visual outcomes.

In our study, the PCO development after 2 different methods of cataract extraction - AquaLase and NeoSoniX - was observed. This is up to knowledge longest period after cataract extraction when the PCO were evaluated by EPCO 2000 and OSCA methods. AquaLase and NeoSoniX are 2 of 4 options provided by INFINITI Vision System (Alcon Laboratories). The major difference is that the AquaLase device does not use ultrasound to break up the lens. Instead, it relies on a relatively high-pressure stream of warm (about 60 ºC), balanced saline solution (BSS) to fragment the nucleus. Several studies have shown that the technology may have applications in polishing the capsule through mechanical washing of epithelial cells from the capsule bag with the fluid pulses.\(^{20-22}\) The reduction of lens epithelial cells has been shown to help prevent PCO (ref.\(^{16}\)), so AquaLase may carry a reduced risk over standard phacoemulsification cataract extraction for the development of PCO (ref.\(^{20,21,23-25}\)). The AquaLase was primary used for liquefication of the cataract in this study. We did not use special settings for lens epithelial cells removal, but because it is very difficult to rupture the posterior capsule using the soft AquaLase needle we believe that the polishing of posterior capsule was more accurate in the AquaLase eyes. NeoSoniX is an option that includes a dedicated hand-piece that produces rotary oscillations of the phacoemulsification tip of up to 2 degrees. This oscillatory motion can be used alone or as an adjunct to ultrasonic energy.\(^{22,26}\) Not many studies have examined the NeoSoniX effect on the PCO alone.

Multiple studies documented that the PCO develops over years. To properly judge the potential of a new IOLs or a surgical method to prevent PCO, a long-term follow-up (usually 3 years or longer) of the included eyes is necessary.\(^{27}\) We observed the PCO at 1-year intervals up to 8 years after cataract surgery; therefore the PCO change over longer period of time was assessed. PCO-induced decrease of VA can be treated by opening the posterior

| EPCO = Evaluation of Posterior Capsule Opacification; OSCA = Open-Access Systematic Capsule Assessment; PCO = posterior capsule opacification. |  |  |  |  |  |
|---|---|---|---|---|
| **Minimal PCO** | **Mild PCO** | **Moderate PCO** | **Severe PCO** | **Total EPCO Index** |
| AquaLase | 0.259 ± 0.263 | 0.031 ± 0.091 | 0.001 ± 0.009 | 0 | 0.324 ± 0.305 |
| 1 year postoperatively | 0.255 ± 0.260 | 0.085 ± 0.130 | 0.035 ± 0.101 | 0.012 ± 0.042 | 0.582 ± 0.506 |
| 3 years postoperatively | 0.310 ± 0.229 | 0.108 ± 0.14 | 0.047 ± 0.18 | 0 | 0.648 ± 0.567 |
| 8 years postoperatively | 0.226 ± 0.296 | 0.018 ± 0.059 | 0 | 0.004 ± 0.019 | 0.298 ± 0.341 |
| NeoSoniX | 0.346 ± 0.306 | 0.039 ± 0.070 | 0.062 ± 0.216 | 0.013 ± 0.037 | 0.594 ± 0.515 |
| 1 year postoperatively | 0.405 ± 0.238 | 0.09 ± 0.127 | 0.025 ± 0.089 | 0.128 ± 0.167 | 0.673 ± 0.542 |
| 3 years postoperatively | 0.405 ± 0.238 | 0.09 ± 0.127 | 0.025 ± 0.089 | 0.128 ± 0.167 | 0.673 ± 0.542 |
| 8 years postoperatively | 0.405 ± 0.238 | 0.09 ± 0.127 | 0.025 ± 0.089 | 0.128 ± 0.167 | 0.673 ± 0.542 |
lens capsule by a Nd:YAG capsulotomy. After the capsulotomy, computer PCO assessment is no longer possible and these dropouts can considerably bias study results. Buehl and associates published an article in which they identified the difficult statistical problems caused by missing data attributable to Nd:YAG laser capsulotomies in long-term PCO trials, especially when a study includes many capsulotomies. They gave possible statistical solutions to the problem on the basis of data obtained from a representative clinical long-term trial of PCO. In our study, only 6 patients required Nd:YAG capsulotomy over the whole follow-up period. The difference in the laser treatment of PCO was not significant between the AquaLase and the NeoSoniX group, so no direct comparison of software outcomes was made. The capsulotomy dropouts were taken into account when making study conclusions. The main purpose of this study was to examine the progression of PCO in eyes after 2 different surgical methods of cataract extraction, AquaLase and NeoSoniX. The PCO quantification was done using the subjective EPCO 2000 software and the objective OSCA system of computer PCO analysis. The OSCA is a system of objective PCO assessment, which is based on location-sensitive entropy-based texture analysis of digital images. Images with no clinical PCO produce very low scores in the analysis. The possible OSCA scores range from 0 (no PCO) to approximate 15 (practical expected maximum). Typical OSCA values for images with very little or no PCO are around 0.5. Values for patients that are deemed to warrant laser capsulotomy are typically around 4 to 5 (ref. ). The EPCO 2000 is a computer-assisted system of PCO morphologic assessment. It incorporates planimetric and grading assessment. The selection process and grading of areas are subjective. The EPCO 2000 scores range from 0 (no PCO) to 4 (maximum) (ref. ). Both systems of PCO analysis measure morphologic severity of PCO (extent and density); as regards the OSCA software, it is in addition with positive weighting toward the central visual axis. We suggest that this is the reason why the correlation between EPCO 2000 and OSCA results was poor over the whole follow-up period. Changes in PCO after AquaLase and NeoSoniX phacoemulsification progressed with time in this study. Progression in EPCO 2000 results was significantly more extensive than in OSCA scores. This means that PCO extent and density progressed (according to the EPCO 2000 and OSCA outcomes), while the progression of opacities in the central part of posterior capsule was slower (according to OSCA scores and to nonsignificant increase in Nd:YAG capsulotomies). The difference in the development of PCO after the AquaLase and the NeoSoniX phacoemulsification method was not significant within a longer period of time. However, the Nd:YAG laser capsulotomy rate was nonsignificantly lower after the AquaLase method over the whole follow-up period. BCVA reached its maximum in 3 years after cataract surgery, then it decreased. Neither relation between total EPCO 2000 index nor OSCA scores and postoperative BCVA for both groups was established 1, 3, and 8 years after cataract surgery. We suggest that it was because there was a very small variability in BCVA in the study (it was 0.8 or better in most cases). PCO was assessed as minimal and its influence on BCVA was probably small, which might also explain why no relation was found between OSCA results and BCVA, as well as EPCO 2000 outcomes and BCVA.

CONCLUSIONS

A comparison of PCO after AquaLase and NeoSoniX phacoemulsification techniques was done 1, 3, and 8 years after surgery. The AquaLase method was slightly better in the majority of observed parameters (EPCO 2000 and OSCA results, Nd:YAG laser capsulotomy rate, BCVA); however, the difference was not significant in most cases. The OSCA system carries out complete PCO analysis; higher the score, the more PCO are in the central part of posterior capsule. Missing values caused by laser capsulotomies have greater impact on the OSCA outcomes than on the EPCO 2000 results. In conclusion, our study has shown that there was only minimal PCO difference between these 2 approaches. AquaLase and NeoSoniX. Both methods of cataract extraction are effective and safe. However, neither AquaLase nor NeoSoniX technique was able to prevent a natural progression of PCO.

ACKNOWLEDGMENTS

Supported by Charles University - Programme P37/07 (PRVOUK).

Author contributions: AS, JN: literature search, manuscript writing and data collection; NJ, PR: final text correction.

Conflict of interest statement: The authors state that there are no conflicts of interest regarding the publication of this article.

REFERENCES

7. Buehl W, Heinzl H, Mittlböeck M, Findl O. Statistical problems caused by missing data resulting from neodyum: YAG laser capsulot-